A phase II trial is ongoing to evaluate the safety and efficacy of the addition of brentuximab vedotin to CHOEP-based chemotherapy (brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone; A+CHEP) followed by brentuximab vedotin consolidation in patients with newly diagnosed CD30-positive PTCL.36 The study population is primarily patients with non-ALCL PTCL, including 38% patients with AITL.37 Early data from this trial have been promising. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.